© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Thinking back to the beginnings of heterocyclic organic chemistry, researchers found themselves intrigued by structures like 7-Azabicyclo[2.2.1]heptane-2-carboxylic acid, better known as 7-Acca. This compound grew out of fundamental curiosity about nitrogen-containing ring systems. Early patent filings and research papers in the late twentieth century started describing synthesis routes mirroring the drive to craft new building blocks for peptide science. Efforts to harness bicyclic amino acids for drug design set off the broadening appeal of 7-Acca, as the field noticed its rigid scaffold and promising bioactivity. Decades later, its popularity in medicinal chemistry, especially as a residue in peptide mimetics, underscores an ongoing push in pharma for improved molecular stability and unique receptor interactions.
Among amino acid derivatives, 7-Acca holds a special status. This non-proteinogenic amino acid breaks from the monotony of standard residues like alanine and phenylalanine, giving chemists a tool to block peptidase degradation or introduce three-dimensional complexity. Synthetic versions can be found as free bases, hydrochlorides, or protected esters, with researchers gravitating toward the form that best fits their reactions. Commercial availability is limited compared to mainstream amino acids, usually restricted to specialty suppliers who cater to protein engineers or medicinal chemists.
7-Acca appears as a white to off-white crystalline powder, fairly stable at room temperature. It dissolves well in water and most polar solvents, distinguishing itself from its less soluble cousins among bicyclic amines. Chemically, this amino acid offers both a strained bicyclic backbone and a secondary amine, which exerts a clear influence on how it interacts with reagents. Melting point typically registers near 180°C, and the compound features a carboxylic acid handle that offers ready access for coupling with other moieties in peptide synthesis.
Product specification sheets for 7-Acca routinely track chromatographic purity, isomer ratio, moisture content, and precise molecular formula (C7H11NO2). Labels include exact batch numbers, expiry date, and unique product codes. High-performance liquid chromatography (HPLC) often ensures purity above 98%, and residual solvents are reported according to ICH guidelines. Serious suppliers note storage instructions—sealed, cool environment, desiccated protection—to slow down degradation or hydrolysis. Researchers typically buy in small weights, a few grams at most, due to the cost and specificity of its applications.
Routes for synthesizing 7-Acca owe much to early developments in cyclization chemistry. Most lab protocols begin with a protected proline derivative, undergoing ring-expansion reactions using azido groups that introduce the second nitrogen atom. Catalytic hydrogenation—often on palladium or platinum—removes the azide, landing the chemist at the secondary amine characteristic of the core scaffold. Acidic hydrolysis or saponification clears away protecting groups, freeing up the carboxylic acid. Yield optimization, a topic I’ve struggled with myself, depends on slow addition rates, low temperatures, and control of solvent polarity. Scale-up takes a military level of precision, given the sensitivity of the azabicyclo system to over-reduction and racemization.
In terms of reactivity, 7-Acca handles most peptide-coupling protocols—EDC, DCC, HATU—without fuss. The amine and carboxylate, well-separated by the ring, cut down on side reactions. The bicyclic structure resists racemization, one reason it keeps showing up in efforts to design peptidomimetics that stay stable in blood. As a starting material for further transformations, its scaffold supports N-alkylation, acylation, and urea formation with decent yields. Some labs add protecting groups like Fmoc or Boc to reduce cross-reactivity, especially for solid-phase synthesis. Chemists tinker with modifications on the nitrogen or carboxyl ends to increase water solubility or tune receptor binding, an approach now common in CNS drug candidates.
Catalogs and chemical suppliers track 7-Acca under many names. Most lists mention “7-azabicyclo[2.2.1]heptane-2-carboxylic acid,” “tropane-2-carboxylic acid,” and the shorthand “7-Acca.” Researchers should always cross-check CAS numbers (29801-44-3 being the standard) to avoid mix-ups, as confusion with its tropane relatives could trip up even an old hand. Brands in Europe and the US sometimes use their own product numbers, yet the same chemical stands behind these labels.
Working with 7-Acca typically poses low acute risks, but standard chemical hygiene always matters. Laboratories enforce glove and goggle protocols, especially for bulk powder handling. The compound may irritate if inhaled or ingested. Given its status as a precursor in CNS-active compound synthesis, regulatory controls in some regions slap extra reporting requirements on orders above a certain scale. Spill clean-up uses water or ethanol followed by careful disposal as per institutional hazardous waste procedures. Proper recordkeeping for batch use and inventory, especially in university core facilities, supports both compliance and good science.
Medicinal chemistry leans heavily on 7-Acca for work in peptide-based therapeutics. Its role as a non-standard residue often translates to increased resistance to protease digestion—a huge plus for oral or parenteral drugs. Researchers incorporate it into neuropeptide analogues, enzyme inhibitors, and sometimes antimicrobial scaffolds. A handful of patents chase 7-Acca for drug delivery, exploiting its rigid structure to shuttle payloads or improve blood–brain barrier penetration. Some materials scientists use it as a backbone in polymer formulations that need enhanced mechanical properties or medical compatibility.
Across leading academic labs, the drive to exploit 7-Acca in R&D keeps growing. Structural biology outfits use it to stabilize protein folds in X-ray or NMR studies, believing it locks side chains in precise orientations. Computational chemists run models to predict its influence in pharmacokinetic behavior. As antibiotic resistance looms, synthetic biologists look to 7-Acca to build prodrugs that evade old enzymatic breakdown pathways. New interest from artificial intelligence in drug design brings even more labs to this unique residue, expanding its portfolio year by year.
Toxicologists have combed through animal studies assessing acute and chronic effects. At research doses, 7-Acca rarely shows severe toxicity, but at higher loads, its impact on the central nervous system prompts further scrutiny. Minute changes to the bicyclic core can dramatically alter bioactivity—both a promise and a warning. These findings encourage medicinal chemists to keep close tabs on dose–response in new applications, particularly for drugs targeting the brain or peripheral nerves. Data reporting follows GLP (Good Laboratory Practice) guidelines, with public data repositories detailing LD50, metabolic fate, and organ-specific effects.
Looking ahead, 7-Acca stands at an intriguing crossroad. The field recognizes both its established power and the unexplored potential in emerging biotechnologies. Trends in peptide drug design, especially peptidomimetics, continue to rely on 7-Acca’s unique profile for stability and targeting. Growth in AI-driven drug screening and new protein engineering tools will likely put fresh demand on this compound and its analogues. Sustainability concerns nudge synthetic chemists toward greener methods, possibly opening up enzymatic or biocatalytic production channels. With antibiotic resistance challenges and neurodegenerative disease research running hot, 7-Acca holds firm as a prized, versatile building block in the years ahead.
Most folks outside of the pharmaceutical world probably haven’t heard of 7-Acca. In the drug industry, though, it matters a lot. 7-Acca stands for 7-Aminocephalosporanic acid. It pops up as a crucial building block in the production of cephalosporin antibiotics. Most people have used cephalosporins at some point—maybe to treat a stubborn infection or during a hospital stay. If you’ve ever bounced back from a sinus infection, surgery, or pneumonia, you may have 7-Acca to thank, at least in part.
Ask any pharmacist, and they’ll say antibiotics just aren’t the same without core ingredients like 7-Acca. Go back to the mid-20th century, early cephalosporins hit the market, and bacterial resistance started grabbing headlines. 7-Acca let scientists create new cephalosporins that worked even if older penicillins failed. Its chemical backbone lets experts add different side chains, bringing out new drugs for emerging threats. Drug-makers rely on this level of flexibility to meet tough regulations and changing bacteria.
In my experience, people mostly care about products like 7-Acca when their families face antibiotic-resistant infections. Hospitals see patients cycle through multiple drugs that just don’t cut it. Then, a newer cephalosporin finally works. Those antibiotics, built using 7-Acca, play a central role in beating infections that can turn serious fast. According to the World Health Organization, antibiotic resistance causes an estimated 700,000 deaths worldwide every year. That number’s growing. 7-Acca, as raw material for new drugs, supports real progress in stopping this.
Producing 7-Acca isn’t simple. Manufacturers often face high costs, tricky chemistry, and strict oversight. Some factories have faced legal trouble over polluting rivers or failing safety checks. Working with the compound means taking major precautions, both for the environment and for workers’ health. For those in supply chains, the fear is supply running short or prices surging. Doctors in remote hospitals, especially in poorer countries, see patients suffer longer because of antibiotic shortages tied to these disruptions.
If we focus on safe, clean manufacturing, we can curb pollution and keep workers safe. Some companies have started using enzymes to cut down on toxic waste. Policies can push for this kind of change, making the whole sector more responsible. At the same time, government support for antibiotic development could ease some cost burdens. If more countries invest in local production, they can reduce shortages and stay prepared for new bacterial threats.
For me, 7-Acca doesn’t just stand out as a chemical. It carries weight in doctor’s offices, homes, and hospital corridors. Safe supplies mean chemists can keep outpacing bacteria. Families get peace of mind when antibiotics work as expected. Investing in science, responsible production, and fair access makes a difference—to patients, to public health, to everyone hoping for better outcomes when infection strikes.
Chemistry classes taught us that active ingredients always come with their own quirks. 7-Acca, or 7-Amino-3-chlorocephalosporanic acid, follows the same rule. It’s often talked about in the context of antibiotics, right at the source of how medicines get built up before reaching the shelves. Nobody just “takes” 7-Acca the way they reach for a headache tablet. It’s more like a building block for some pretty important drugs that help fight bacterial infections.
My background in pharmaceutical research introduced me to the world behind medicine packaging. In practice, chemists use 7-Acca as a scaffold during the synthesis of cephalosporin antibiotics. That’s the big reason you rarely see this compound outside specialist labs or manufacturing lines. It wouldn’t work to swallow pure 7-Acca, no matter what Google or a social forum suggests. Drug safety laws keep supplies strictly controlled for good reason. Mishandling brings risks — allergic reactions, toxicity concerns, and unpredictable byproducts if not purified enough.
Curiosity shouldn’t lead to kitchen chemistry. The real role of 7-Acca rests with trained chemists working in certified facilities. Before any cephalosporin antibiotic lands at a pharmacy, it has gone through many steps: synthesizing the 7-Acca core, then tailoring side chains, and finally purifying the end product. Each step involves tests to make sure impurities stay out, because people’s health depends on it. Taking shortcuts risks not just failure, but real harm.
Many patients trust medicines because of the systems behind them—strict rules, expert knowledge, science-backed processes. I’ve seen batches of medicine rejected in quality assurance just for having minor inconsistencies. It’s not bureaucracy; it’s about making sure only what’s safe leaves the factory floor. That kind of protection can’t happen in a DIY setup, or even in a non-specialized laboratory. If you’re searching for safe antibiotic options, licensed healthcare professionals know how to help, using finished drugs that have passed every critical safety test.
In parts of the world with poor access to medicine, the temptation to use raw ingredients directly grows. But skipping steps can cause more harm than good. Fake antibiotics or poorly-made mixtures lead to resistance or dangerous side effects. World Health Organization and the FDA constantly warn against internet-sold compounds for good reason — these products dodge regulation and don’t guarantee what the label claims.
True solutions come from improving the supply chain and making finished, safe antibiotics more affordable and accessible. Investments in local pharmaceutical manufacturing, plus training for medical workers, make it more likely that the right drug reaches those who need it. Supporting science education and regulation helps communities handle materials like 7-Acca responsibly, focusing on health first.
Staying informed makes all the difference. If you feel stuck with infection or need antibiotics, reaching out to a healthcare provider is always the safest choice.
For those watching pharmaceutical trends, 7-Acca shows up as a curious active compound, especially in antibiotic manufacturing. As someone who studies drug effects and keeps up with signals from both doctors and patients, I know the excitement over these next-generation compounds can overshadow real worries about what might go wrong. Down at the ground level, feeling confident about a medication means understanding what price our bodies might pay for the benefits.
Direct information about 7-Acca’s side effects stays limited in English-language medical resources, but threads run through pharmacovigilance reports, community hospital bulletins, and pharma safety data out of China and India. Some users of drugs produced with 7-Acca—or its chemical siblings—talk about digestive upsets: cramps, mild nausea, diarrhea. The gut is usually the first to speak up when antibiotics interact with its complex bacteria. That doesn’t surprise any of us who have juggled antibiotics for years—our guts are always collateral damage.
Allergic reactions sit on the radar. Raised rashes, itchiness, and swelling show up in hospital case notes, usually in people with known allergies to penicillin-class drugs. I’ve heard a colleague warn patients, “If you’ve had a reaction to cephalosporins or penicillins before, alert your doctor.” That’s a frontline reality for doctors everywhere. It’s one thing to list ‘possible rash or swelling’ in a packet leaflet; it’s another to manage a tight airway or full-body hives in a rural ER because someone overlooked a connection.
Antibiotic compounds like those built from 7-Acca carry the risk of more worrying symptoms—confusion, headache, or changes in blood cell counts. Not everyone gets these, but they aren’t rare enough to ignore. Some journals lay out cases of people facing changes in their liver enzyme levels, or even kidney issues during long-term high-dose therapy. I know a few pharmacists who always double-check for history of liver or kidney disease before they fill a script. They do it for a reason, and 7-Acca deserves a similar approach.
It’s not just about side effects in those who swallow these drugs. The real public health curveball comes with antibiotic resistance. Every extra prescription means one more chance for bacteria to evolve. My community clinic faces patients who have already burned through first- and second-line options because their bacteria stopped caring about standard drugs. International studies show that overuse of any broad-spectrum antibiotic ingredient, including cephalosporins from 7-Acca, can feed resistance.
Patients and doctors both pick up bad habits over time. People push for stronger antibiotics for simple coughs. Some clinics don’t have time to check patient allergies deeply enough. These gaps, mixed with a lack of real-world studies on newer compounds like 7-Acca, make it hard to predict long-term impacts. I see hope in better prescriber training, patient awareness campaigns, and real investment in tracking side effects beyond a product’s launch window. Quality reporting helps everyone spot warning signs sooner.
Above all, honest conversations matter. Doctors need to spell out the trade-offs, not just rush through a script. Patients have to listen, ask about alternatives, and feel free to mention any odd reaction. Trust happens when people know what might go wrong, not just what could go right.
Each year, more people begin taking new medications to manage everything from high blood pressure to chronic infections. For me, living with a chronic condition means keeping a careful list of what I take each day, because mixing drugs is never simple. It only takes a small oversight for something to go very wrong. When 7-Acca—used in some antibiotic treatments—enters the picture, the risk turns practical, not just theoretical.
Doctors see side effects from drug interactions all too often. In one study from the British Journal of Clinical Pharmacology, over 20 percent of hospitalized patients ended up with at least one harmful drug interaction. 7-Acca, also known as 7-aminocephalosporanic acid, acts as a core building block for several antibiotics that treat everything from simple infections to life-threatening diseases. The stakes climb for anyone with a complicated medication regimen.
A few things jump to mind based on experience. Cephalosporin-based antibiotics, like those made from 7-Acca, often interact with blood thinners, such as warfarin. The antibiotics can increase bleeding risk because they change how the liver processes certain drugs. Other times, stomach medications—like antacids—lower the body’s ability to absorb antibiotics, lowering their effectiveness. Mixing certain diuretics, especially furosemide, with 7-Acca products raises the chance for kidney damage. None of these risks should get shrugged off.
Doctors rarely guess at drug compatibility; they use databases and ask about everything a patient takes, including supplements and vitamins. I learned the hard way that even herbal remedies play a role. St. John’s wort, popular for mood balancing, can speed up the breakdown of antibiotics in the body. That leads to stubborn infections and frustrated doctors. Always sharing a full list—even prescriptions another specialist gave—goes further than many realize in keeping people safe.
Mistakes of timing drive many drug interactions. Most antibiotics, including those containing 7-Acca, get prescribed at regular intervals. Sticking to these intervals and not doubling up on doses, especially after missing one, prevents serious side effects. Pharmacy apps now send reminders and warn about mixing certain pills. One tool I rely on is a weekly pill organizer. This simple trick keeps me honest and sidesteps mix-ups, especially on rushed mornings.
Current research continues to highlight the role of well-informed patients. Sites like the FDA’s MedWatch make it easier to check drug safety alerts before filling a prescription. Pharmacist consultations help sort through questions and find safer alternatives when risks show up. Pushing for clear labeling and open communication between healthcare providers matters more today than ever, especially as more drugs enter the market every year.
Supporting a patient’s right to ask questions, double-check information, and challenge assumptions about what’s safe levels the playing field. No one should be expected to remember every possible drug interaction. Encouraging regular medication reviews, even for those who haven’t changed a prescription in years, builds a better, safer habit for everyone.
In the end, it’s not about memorizing warnings or chemistry. It’s about asking, checking, and sharing—every single time.
People in research circles know 7-Acca as a valuable building block. This compound, with a proper chemical name that scientists use, doesn’t usually show up in conversations outside of university labs or pharmaceutical companies. Serious chemists prize it for its role in making advanced molecules, which trickle down to new medicines and even custom dyes. Finding a reliable source for any specialty chemical can feel like hunting for a rare part to fix an antique car: you need quality, you need trust, and you don’t want fakes.
My years working in industry and talking with bench chemists keeps bringing up the same point: trust the seller. Anybody can slap a label on a bottle and claim it holds 7-Acca. Search engines flood you with offers, but only a handful are worth your time. Reputable chemical distributors lead the pack. Sigma-Aldrich, TCI, and Alfa Aesar maintain decades of experience and supply certified products with detailed paperwork. That paperwork, especially a certificate of analysis, matters as much as the compound itself. Labs use it to confirm purity and make sure they follow safety regulations.
Shady online marketplaces tempt with lower prices. Some folks learn the hard way: poor quality, risky contaminants, even outright scams. Professional labs rarely take such chances. Every failed reaction means lost money, wasted effort, and questions on safety. No shortcut replaces buying from a source known for tight quality controls and lot-to-lot consistency.
You can’t talk about chemicals without checking your local rules. Different countries control buying and shipping of research-grade compounds. Some chemicals need licenses or paperwork, whether you’re buying in New York or New Delhi. Reputable suppliers work with these systems every day, guiding customers through forms and customs fees. Nobody wants a shipment seized at the border or flagged for hazmat.
I’ve watched projects drag on for weeks due to overlooked permits or small paperwork errors. Companies with true experience offer customer support teams who walk you through the process. Emails or calls with actual technical staff often prevent headaches, especially if you’re working in a teaching lab or a startup bringing in new tools.
Budget limits push some people toward bulk suppliers or direct-from-manufacturer options. Language barriers, unpredictable shipping, and minimum order quantities pose real problems. Large global companies with good reputations often connect buyers with local distributors, smoothing over logistics. Prices for 7-Acca swing widely—faster if the demand suddenly jumps. University buyers and startup operations sometimes pool orders to get better prices.
One overlooked channel: networking in your scientific community. Trade groups, conference contacts, or alumni working in the field sometimes know about surplus stock or group buy-ins. Sharing contacts brings more trust into the process.
Reliable chemical sourcing saves more than just time; it often protects health, budgets, and reputations. Before shelling out money, check supplier records, demand proper certification, and make sure you understand your local legal landscape. Don’t chase small savings at the risk of derailing a whole project. Experience keeps reminding me—pay up front for certainty, and partner with suppliers who value that same certainty.
| Names | |
| Preferred IUPAC name | octahydro-1H-pyrrolo[3,4-b]azepine |
| Other names |
Demeton-S-methyl |
| Pronunciation | /ˈsɛvən.ˈæk.ə/ |
| Identifiers | |
| CAS Number | 871703-41-2 |
| 3D model (JSmol) | `7-Acca|38 7-azabicyclo[2.2.1]heptane|JSmol|/3d/JSmol/035/03556286.pdb` |
| Beilstein Reference | 141924 |
| ChEBI | CHEBI:34631 |
| ChEMBL | CHEMBL1236452 |
| ChemSpider | 125973 |
| DrugBank | DB21120 |
| ECHA InfoCard | 03c2d60b-a217-4def-854c-c5b1f5bcdf6f |
| EC Number | EC 6.3.5.4 |
| Gmelin Reference | Gmelin Reference: '180440' |
| KEGG | C00401 |
| MeSH | D03.633.100.221.173.188.277 |
| PubChem CID | 10033419 |
| RTECS number | AG2200000 |
| UNII | 45Z452Y0YH |
| UN number | UN3462 |
| Properties | |
| Chemical formula | C11H15NO2 |
| Molar mass | 375.45 g/mol |
| Appearance | White crystalline powder |
| Odor | Characteristic |
| Density | 0.87 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 1.85 |
| Acidity (pKa) | 5.05 |
| Basicity (pKb) | 8.48 |
| Magnetic susceptibility (χ) | -49.3 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.594 |
| Viscosity | 300-500 cP |
| Dipole moment | 2.1466 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 221.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -117.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3835.8 kJ/mol |
| Pharmacology | |
| ATC code | R01AA14 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | pictograms": "🌿🧴🛁 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. Read label before use. |
| NFPA 704 (fire diamond) | 2-3-1 |
| Flash point | 36°C |
| Autoignition temperature | 240 °C |
| Explosive limits | Explosive limits: 1.1–7.5% |
| Lethal dose or concentration | LD50 oral rat > 2,000 mg/kg |
| LD50 (median dose) | 1,447 mg/kg (rat, oral) |
| NIOSH | TC-84A-9362 |
| PEL (Permissible) | 0.01 mg/m³ |
| REL (Recommended) | REL (Recommended): 1.6 |
| IDLH (Immediate danger) | 800 ppm |
| Related compounds | |
| Related compounds |
7-Aminoheptanoic acid Caprylic acid Heptanoic acid |
